Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Cystatin C Blood Levels Estimate Kidney Function

By LabMedica International staff writers
Posted on 23 Sep 2013
Cystatin C, a newer kidney function marker, is becoming more widely available and in some settings provides improved estimates of kidney function.

The use of blood levels of cystatin C to estimate kidney function, alone or in combination with creatinine levels, strengthens the association between kidney function and risks of death and end-stage renal disease.

An international team of scientists, known as the Chronic Kidney Disease Prognosis Consortium, based at the Johns Hopkins University (Baltimore, MD, USA) performed a meta-analysis of 11 general-population studies, with 90,750 participants from the USA, Europe, and Australia. More...
They also examined five studies of 2,960 participants with chronic kidney disease for whom standardized measurements of serum creatinine and cystatin C were available.

The team compared the association of kidney function, as calculated by the measurement of creatinine, cystatin C, or the combination of creatinine and cystatin C, with the rates of death, death from cardiovascular causes, and end-stage kidney disease, and they compared kidney disease stages that were classified alternatively by creatinine or cystatin C.

The analyses of using cystatin C demonstrated that the risks associated with declining kidney function emerge when kidney function reaches approximately 85 mL per minute per 1.73 m2, much earlier than the threshold of chronic kidney disease which is 60 mL/min/1.73 m2. In contrast, with creatinine based kidney function estimates, these risks of kidney function cannot be observed until kidney function is below 60 mL/min/1.73 m2, by which time chronic kidney disease has already developed. The kidney function stages categorized by cystatin C were much better at reflecting future risk than were the stages based upon creatinine estimates of kidney function.

Michael Shlipak, MD, MPH, from the University of California (San Francisco, CA, USA) and lead author of the article, said “Clearly cystatin C defines an important preclinical period of reduced kidney function before chronic kidney disease can be diagnosed with creatinine alone, and this period may last one to two decades. Cystatin C allows patients' kidney function to be categorized more accurately; the use of cystatin C in clinical medicine could help us to be more precise in the diagnosis of chronic kidney disease, and in the future to target high-risk patients for treatment in order to prevent chronic kidney disease." The study was published on September 5, 2013, in the New England Journal of Medicine.

Related Links:
Johns Hopkins University
University of California


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
Automatic CLIA Analyzer
Shine i6000
New
Gold Member
Fully-auto Specific Protein (Nephelometry) Analyzer
PA240
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: A new study links broad genomic sequencing before first-line therapy to longer survival, supporting its role in treatment decisions (Image Credit: Shutterstock)

Study Supports Broad Genomic Profiling Before First-Line Lung Cancer Treatment

Biomarker testing plays a critical role in advanced non-small cell lung cancer by identifying patients who may benefit from targeted therapies. However, testing only one or two genes can miss actionable... Read more

Immunology

view channel
Image: The findings underscore the importance of aligning allergy testing with clinical history and diagnostic guidelines to reduce inappropriate testing and its consequences (Image Credit: iStock)

Survey Finds Gap Between Food Allergy Testing Awareness and Clinical Practice

Food allergy evaluation can be challenging when laboratory results do not match clinical symptoms. Broad food allergy panels may detect sensitization without confirming an actual allergy, potentially leading... Read more

Industry

view channel
Image Credit: iStock

C2N Makes PrecivityAD2 Alzheimer’s Blood Test Available to Clinicians

Diagnosing Alzheimer’s disease can be challenging, particularly in patients with mild cognitive impairment or early dementia. Assessing brain amyloid pathology can guide clinical decisions, but diagnostic... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.